Screening period
Follow-up period Treatment period
Repeat the study treatment unless subjects meet any discontinuation criteria Request for study withdrawal by the subject n=3
Death n=1
Meet the criteria for discontinuation n=62
• Progressive disease n=52 • Clinical symptoms aggravated because of PD n=2 • ≥ grade 2 interstitial pneumonia n=4 • Due to AEs, nivolumab has not been administered within 6 weeks after the last dose n=2 • Discontinuation based on the subject's efficacy and safety data n=3 AEs and Grade observed between the start date of the first administration of the study drug and 28 days after the last dose or the start date of subsequence anti-cancer therapy after the last dose whichever comes first were tabulated. AEs and Grade observed between the start date of the first administration of the study drug and 28 days after the last dose or the start date of subsequence anti-cancer therapy after the last dose whichever comes first were tabulated. 
